Therapix Biosciences (THXBY) 4.0100 $THXBY
Therapix Biosciences Signed a Binding MOU With a Swiss Pharmaceutical Development Company, to Receive a License to Use a Formulation for Ultralow-Dosage Administration
PR Newswire - Tue Jun 21, 7:00AM CDT
Therapix Biosciences(OTCQB: THXBY) (TASE: THXBY), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today (Wednesday) that it entered into a binding memorandum of understandings with a Swiss pharmaceutical development company, to receive a worldwide and exclusive license to use the formulation for sublingual administration of ultralow dosages of THC, for the purpose of developing and marketing the formulation in the indications on which the Company has chosen to focus, with an emphasis on cognitive impairments.
Therapix Biosciences Filed an Application with the FDA to Approve an "Orphan" Designation for the Drug Developed Based on the Entourage Technology for Treating Tourette's Syndrome
PR Newswire - Wed Jun 15, 7:00AM CDT
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that it filed an application with the U.S. Food and Drug Administration to approve an orphan drug designation for a drug (THX-RS01) developed based on the entourage technology, which combines cannabinoid substances in treating Tourette syndrome.
Therapix Biosciences ADRs Begin Trading on the OTCQB(R)
GlobeNewswire - Tue Oct 07, 8:06AM CDT
Therapix Bio (TASE:TRPX) (OTC:THXBY) today announced that its American Depository Receipts (ADRs) have been registered and approved for trading on OTCQB(R). The ADRs, each representing 20 ordinary shares, began trading on October 6, 2014 under the symbol THXBY.
Therapix Biosciences Signed a Binding MOU With a Swiss Pharmaceutical Development Company, to Receive a License to Use a Formulation for Ultralow-Dosage Administration
PR Newswire - Tue Jun 21, 7:00AM CDT
Therapix Biosciences(OTCQB: THXBY) (TASE: THXBY), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today (Wednesday) that it entered into a binding memorandum of understandings with a Swiss pharmaceutical development company, to receive a worldwide and exclusive license to use the formulation for sublingual administration of ultralow dosages of THC, for the purpose of developing and marketing the formulation in the indications on which the Company has chosen to focus, with an emphasis on cognitive impairments.
Therapix Biosciences Filed an Application with the FDA to Approve an "Orphan" Designation for the Drug Developed Based on the Entourage Technology for Treating Tourette's Syndrome
PR Newswire - Wed Jun 15, 7:00AM CDT
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that it filed an application with the U.S. Food and Drug Administration to approve an orphan drug designation for a drug (THX-RS01) developed based on the entourage technology, which combines cannabinoid substances in treating Tourette syndrome.
Therapix Biosciences ADRs Begin Trading on the OTCQB(R)
GlobeNewswire - Tue Oct 07, 8:06AM CDT
Therapix Bio (TASE:TRPX) (OTC:THXBY) today announced that its American Depository Receipts (ADRs) have been registered and approved for trading on OTCQB(R). The ADRs, each representing 20 ordinary shares, began trading on October 6, 2014 under the symbol THXBY.
